This phase 3 clinical trial followed 596 patients with moderate to severe asthma in Latin American centers. The study looked at the effects of dupilumab, a medication given every two weeks, over a period of up to 148 weeks. Researchers tracked lung function, flare-up rates, and quality of life scores to see how the treatment performed over time.
The results showed that patients maintained better lung function through week 96. The rate of severe asthma flare-ups remained low throughout the study. Additionally, patients reported improvements in their quality of life and asthma control scores through week 48. The study also noted a decrease in specific type 2 biomarkers over time.
While the results are promising, it is important to note that this was an open-label study, which means the researchers and patients knew which treatment was being given. The safety profile was consistent with what is already known about dupilumab. These findings suggest that the medication may offer long-term benefits for certain asthma patients, but you should talk to your doctor to see if it is right for your specific needs.
